Roseburia hominis (R. hominis) is a relatively newly recognized probiotic bacteria species. It can penetrate the mucus layer and stick to the surface of host intestinal epithelial cells, which promotes the probiotic potential of these gut bacteria. It is a promising candidate strain for live biotherapeutic products (LBP). At Creative Biolabs, we are highly experienced in LBP development. We team up with you to understand your needs and develop customized solutions to your satisfaction.
R. hominis cells are Gram-variable to Gram-negative, slightly curved rods, it is a flagellated gut anaerobic commensal bacterium, producing short-fatty acids, the optimum growth temperature is 37℃. Good growth occurs on M2GSC agar at 37℃ and after incubation for 48 h forms creamy white translucent colonies with entire edges, approximately 1-3 mm in diameter. One of the most proficient butyrate producers in the human gut is R. hominis A2-183, which produces up to 20 mM of butyrate. R. hominis is a representative Roseburia species. Altered Roseburia abundance may affect multiple metabolic pathways and is associated with several diseases, including irritable bowel syndrome, ulcerative colitis, obesity, type 2 diabetes, neurological disorders, and allergies.
Fig.1 Scanning electron micrograph of R. hominis sp. nov. strain A2-183T, showing a flagellar bundle. (Duncan, 2006)
Scientists have investigated the mechanisms of R. hominis-host cross talk using both murine and in vitro models. In R. hominis, host intestinal colonization upregulated genes involved in conjugation/mobilization, metabolism, motility, and chemotaxis. In host cells, bacterial colonization upregulated genes associated with antimicrobial peptides, intestinal barrier function, toll-like receptor (TLR) signaling, and T-cell biology. Treatment with the R. hominis bacterium protected against DSS-induced colitis. These data reveal the immunomodulatory properties of R. hominis, suggesting a potential therapeutic benefit of R. hominis in the treatment of UC.
Male Sprague-Dawley germfree rats were orally administered with or without R. hominis. R. hominis treatment significantly increased the intestinal melatonin level. The concentrations of propionate and butyrate in the intestinal contents were significantly elevated after the gavage of R. hominis. Propionic acid and butyric acid, metabolites of R. hominis, can promote the synthesis of intestinal melatonin by increasing 5-HT levels and promoting p-CREB-mediated Aanat transcription, providing potential targets for the improvement of intestinal diseases. This study provides novel evidence that microbiota intervention could be a potential therapeutic strategy for some intestinal diseases, such as IBS and inflammatory bowel disease, by increasing intestinal melatonin.
Fig.2 Potential mechanisms of R. hominis in intestinal melatonin synthesis. (Song, 2021)
We supply a variety of R. hominis strains of different preservation numbers as below. If you need other strains, please contact us.
Creative Biolabs’ team is diverse, knowledgeable, and agile, with a solid leadership universally recognized in the world of LBP. With our effective tools, extensive knowledge, unwavering support, assuring our partner’s projects go forward successfully. If you are interested in our R. hominis related products and services, please feel free to contact us for more.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.